SG11201909113VA - Dna methylation and mutational analysis methods for bladder cancer surveillance - Google Patents

Dna methylation and mutational analysis methods for bladder cancer surveillance

Info

Publication number
SG11201909113VA
SG11201909113VA SG11201909113VA SG11201909113VA SG 11201909113V A SG11201909113V A SG 11201909113VA SG 11201909113V A SG11201909113V A SG 11201909113VA SG 11201909113V A SG11201909113V A SG 11201909113VA
Authority
SG
Singapore
Prior art keywords
california
international
penobscot
redwood city
drive
Prior art date
Application number
Inventor
Margarita Lopatin
Athanasios Tsiatis
Christopher N Silk
David P Miller
Michael Crager
Phillip Febbo
Dejan Knezevic
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of SG11201909113VA publication Critical patent/SG11201909113VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

1 0.2 0.3 OA 0.5 0.6 0.7 0.8 0.9 P091.444oD quantile speciriCitc , 52 .41 ?•i , 77.9% (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 November 2018 (22.11.2018) WIP0 I PCT Hu omit VIII °nolo olotill ommoolio iflo oimIE (10) International Publication Number WO 2018/213550 Al (51) International Patent Classification: C12Q 1/6886 (2018.01) (21) International Application Number: PCT/US2018/033146 (22) International Filing Date: 17 May 2018 (17.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/508,274 18 May 2017 (18.05.2017) US (71) Applicant: GENOMIC HEALTH, INC. [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). (72) Inventors: LOPATIN, Margarita; 301 Penobscot Dri- ve, Redwood City, California 94603 (US). TSIATIS, Athanasios; 301 Penobscot Drive, Redwood City, Califor- nia 94603 (US). SILK, Christopher N.; 301 Penobscot Drive, Redwood City, California 94603 (US). MILLER, David P.; 1080 Peralta Avenue, Albany, California 94706 (US). CRAGER, Michael; 301 Penobscot Drive, Red- wood City, California 94603 (US). FEBBO, Phillip; 301 Penobscot Drive, Redwood City, California 94603 (US). KNEZEVIC, Dej an; 301 Penobscot Drive, Redwood City, California 94603 (US). (74) Agent: DOHERTY, Elizabeth A. et al.; 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: DNA METHYLATION AND MUTATIONAL ANALYSIS METHODS FOR BLADDER CANCER SURVEILLANCE 1.00 099 0.98 0.97 0.96 High Risk Recur t11 1 \"I 1.0 0.8 0.6 0.4 02 99 . 7% 98.8% 0.05 0.0 0.1 0.2 0.3 0.4 0.5 0.8 0.7 0.8 69 0.0 Population qthar669 Sensith.My 1.0 0.6 0.8 0.6 0.6 0.4 0) 0.2 w. a2 04 96.596 0.0 0.0 \" 0.0 0.1 02 0.3 04 0.5 D.6 0.7 0.8 0.9 1.0 popw.ation qumUe 0.0 01 0.2 201 0.4 6.5 OA 0.7 0.6 0.9 1.0 Popti;aton quantilt., Fig. 1 00 (57) : The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for O presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence. C [Continued on next page] WO 2018/213550 Al MIDEDIMOHNIIME1010010ElliOMMINUMEHOIS EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201909113V 2017-05-18 2018-05-17 Dna methylation and mutational analysis methods for bladder cancer surveillance SG11201909113VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508274P 2017-05-18 2017-05-18
PCT/US2018/033146 WO2018213550A1 (en) 2017-05-18 2018-05-17 Dna methylation and mutational analysis methods for bladder cancer surveillance

Publications (1)

Publication Number Publication Date
SG11201909113VA true SG11201909113VA (en) 2019-10-30

Family

ID=62528860

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912359XA SG10201912359XA (en) 2017-05-18 2018-05-17 Dna methylation and mutational analysis methods for bladder cancer surveillance
SG11201909113V SG11201909113VA (en) 2017-05-18 2018-05-17 Dna methylation and mutational analysis methods for bladder cancer surveillance

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912359XA SG10201912359XA (en) 2017-05-18 2018-05-17 Dna methylation and mutational analysis methods for bladder cancer surveillance

Country Status (12)

Country Link
US (2) US11649506B2 (en)
EP (1) EP3625369B1 (en)
JP (1) JP2020519296A (en)
CN (1) CN110621788A (en)
AU (1) AU2018269030A1 (en)
BR (1) BR112019022360A2 (en)
CA (1) CA3057440A1 (en)
ES (1) ES2973607T3 (en)
IL (1) IL269707A (en)
MX (1) MX2019012260A (en)
SG (2) SG10201912359XA (en)
WO (1) WO2018213550A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114634982A (en) * 2020-12-15 2022-06-17 广州市基准医疗有限责任公司 Method for detecting polynucleotide variation
CN113621691A (en) * 2021-09-27 2021-11-09 广东省妇幼保健院 Method and kit for directly detecting CpG methylation of KLF1 gene promoter region based on first-generation sequencing technology
CN116013528B (en) * 2023-01-10 2023-11-24 中山大学孙逸仙纪念医院 Bladder cancer postoperative recurrence risk prediction method, device and medium combining with FISH detection
CN116987787A (en) * 2023-06-09 2023-11-03 北京泛生子基因科技有限公司 Apparatus for detecting recurrence of bladder cancer and computer readable storage medium
CN117604101A (en) * 2023-09-11 2024-02-27 北京橡鑫生物科技有限公司 Gene marker combination, kit and detection method
CN118006781A (en) * 2024-02-27 2024-05-10 广州中鑫基因医学科技有限公司 Marker, primer set, high-sensitivity and high-specificity kit and detection method for detecting urothelial cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896180B1 (en) 2005-06-23 2011-11-23 Biocartis SA Cartridge, system and method for automated medical diagnostics
EP3048176B1 (en) * 2009-04-20 2019-03-06 Erasmus University Medical Center Rotterdam Method of diagnosing bladder cancer
WO2010149782A1 (en) * 2009-06-26 2010-12-29 Epigenomics Ag Methods and nucleic acids for analysis of bladder cell proliferative disorders
CN103417983A (en) * 2012-05-18 2013-12-04 北京大学 Novel apoptosis-related molecule TMEM106A and applications thereof
US20150292030A1 (en) * 2012-11-27 2015-10-15 Board Of Regents, The University Of Texas System Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
WO2014183093A1 (en) * 2013-05-10 2014-11-13 University Of Southern California Dna methylation biomarkers for bladder cancer
EP3099822A4 (en) * 2014-01-30 2017-08-30 The Regents of the University of California Methylation haplotyping for non-invasive diagnosis (monod)
GB201511152D0 (en) * 2015-06-24 2015-08-05 Ucl Business Plc Method of diagnosing bladder cancer

Also Published As

Publication number Publication date
AU2018269030A1 (en) 2019-10-17
ES2973607T3 (en) 2024-06-20
WO2018213550A1 (en) 2018-11-22
US11649506B2 (en) 2023-05-16
CA3057440A1 (en) 2018-11-22
EP3625369B1 (en) 2024-02-14
BR112019022360A2 (en) 2020-05-19
MX2019012260A (en) 2020-01-27
JP2020519296A (en) 2020-07-02
IL269707A (en) 2019-11-28
US20230374604A1 (en) 2023-11-23
EP3625369A1 (en) 2020-03-25
SG10201912359XA (en) 2020-02-27
CN110621788A (en) 2019-12-27
US20200165686A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
SG11201909113VA (en) Dna methylation and mutational analysis methods for bladder cancer surveillance
SG11201908564RA (en) Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions
SG11201804957VA (en) Neoantigen identification, manufacture, and use
SG11201908288XA (en) Configurable annotations for privacy-sensitive user content
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201803666WA (en) Single image detection
SG11201807068WA (en) Devices and methods for rapid pcr
SG11201806609TA (en) Cancer evolution detection and diagnostic
SG11201901371XA (en) Methods for the detection of genomic copy changes in dna samples
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201907607VA (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901432YA (en) Immunotherapy markers and uses therefor
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201907764PA (en) Methods for screening infections
SG11201810924WA (en) System and method for secondary analysis of nucleotide sequencing data
SG11202000114TA (en) Hybrid inspection system for efficient process window discovery
SG11201805115PA (en) Detection and quantification of target nucleic acid sequence of a microorganism
SG11201808740TA (en) Multiplex nucleic acid assay methods capable of detecting closely related alleles, and reagents therefor
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201804020YA (en) Assays and methods for selecting a treatment regimen for a subject with leukemia
SG11201810019RA (en) Methods of human leukocyte antigen typing
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201901991QA (en) Methods of detecting per cell pd-l1 expression and uses thereof
SG11201807501UA (en) Method and system for imaging